Skip to main content

Table 3 Characteristics of nr-axSpA patients at initiation of first TNFi treatment with available follow-up visit at 1 year (patients with co-morbid fibromyalgia excluded)

From: Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort

Parameter A. Nr-axSpA patients with available follow-up visit at 1 year B. Nr-axSpA patients still on TNFi treatment at 1 year
N, 120 Men, N = 58 Women, N = 62 p N, 83 Men, N = 45 Women, N = 38 p
Age, years 120 36.0 (10.8) 38.6 (11.4) 0.25 83 34.6 (10.3) 39.2 (13.4) 0.16
Age at onset, years 120 27.7 (8.4) 27.9 (8.2) 0.78 83 27.4 (8.0) 27.4 (7.5) 0.89
Symptom duration, years 120 8.3 (9.5) 10.7 (11.3) 0.27 83 7.2 (7.8) 11.7 (12.2) 0.12
Diagnostic delay, years 120 4.7 (8.6) 7.3 (10.1) 0.03 83 3.0 (5.3) 7.4 (10.3) 0.02
HLA-B27 positive, % 110 79.6 73.2 0.50 78 83.3 77.8 0.58
Prior sacroiliitis on MRI, % 112 67.9 67.8 1.00 77 66.7 65.7 1.00
BASDAI 108 5.4 (2.0) 6.1 (1.6) 0.05 74 5.2 (2.0) 5.9 (1.6) 0.09
Physician Global Assessment 115 5.1 (1.9) 4.8 (1.7) 0.54 81 5.3 (2.0) 4.7 (1.8) 0.28
Patient Global Assessment 109 6.6 (2.2) 6.7 (1.9) 1.00 75 6.5 (2.2) 6.4 (2.0) 0.89
ASDAS 100 3.4 (0.9) 3.4 (0.7) 0.63 69 3.4 (0.9) 3.4 (0.6) 0.90
ASDAS > 2.1, % 100 88.9 94.5 0.46 69 91.7 97.0 0.62
CRP (mg/l), median (IQR) 111 7.0 (2.0; 15.0) 7.0 (3.0; 10.0) 0.63 77 7.3 (3.0; 19.5) 7.0 (3.5; 10.5) 0.37
Elevated CRP, % 111 47.2 43.1 0.71 77 54.8 42.9 0.36
BASFI 109 3.7 (2.4) 3.5 (2.4) 0.61 75 3.5 (2.4) 3.2 (2.3) 0.53
BASMI 102 1.2 (1.1) 1.4 (1.2) 0.37 70 1.1 (1.1) 1.2 (1.3) 0.88
EQ-5D 103 53.7 (22.8) 57.6 (17.8) 0.52 70 55.6 (21.7) 59.2 (15.7) 0.65
Current periph. arthritis,% 116 47.4 47,5 1.00 82 46.7 54.0 0.66
Number of swollen joints 113 0.7 (1.2) 1.2 (2.6) 0.83 80 0.8 (1.3) 1.5 (2.9) 0.52
Current enthesitis, % 115 80.7 86.2 0.46 82 80.0 86.5 0.56
Modified MASES 114 2.4 (2.6) 3.7 (3.2) 0.02 81 2.1 (2.2) 3.4 (2.7) 0.03
Dactylitis ever, % 118 16.1 19.4 0.81 82 11.4 21.1 0.36
csDMARDs ever, % 120 31.0 40.3 0.34 83 26.7 36.8 0.35
Taking NSAIDs, % 109 94.1 86.2 0.21 76 100.0 85.7 0.02
Current smoking, % 102 28.9 15.8 0.15 68 26.5 8.8 0.11
Body mass index 120 25.9 (4.2) 24.0 (4.4) 0.002 83 25.6 (4.2) 23.6 (4.7) 0.004
Type of TNFi, % 120    0.69 83    0.38
• Adalimumab   34.5 43.5    35.6 50.0  
• Certolizumab   1.7 0.0    2.2 0.0  
• Etanercept   19.0 16.1    20.0 10.5  
• Golimumab   22.4 24.2    20.0 26.3  
• Infliximab   22.4 16.1    22.2 13.2  
  1. A is the characteristics of patients starting TNFi included in the response/tolerance analyses: response in patients with available outcome at 1 year, patients having discontinued the first TNFi in the meantime being considered non-responders. B is the characteristics of patients starting TNFi included in the completer analyses at 1 year. Except where indicated otherwise, values are the mean (SD). Data in bold are statistically significant. Patients with co-morbid fibromyalgia were excluded from these analyses. ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein levels, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, EQ-5D EuroQol 5-domains, HLA-B27 human leucocyte antigen B27, MASES Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers to the inclusion of the plantar fascia in the count, nr-axSpA nonradiographic axial spondyloarthritis, NSAIDs nonsteroidal anti-inflammatory drugs, TNFi tumor necrosis factor inhibitor